Viatris (VTRS) Liabilities from Discontinued Operations (2022 - 2024)
Viatris (VTRS) posted Liabilities from Discontinued Operations of $32.8 million for Q2 2024, down 86.03% on a QoQ basis from $234.8 million in Q1 2024.
Analysis
Viatris (VTRS) Liabilities from Discontinued Operations (2022 - 2024) Analysis & Trends
Viatris has reported Liabilities from Discontinued Operations for 3 years, with the latest figure at $32.8 million in Q2 2024.
- On a quarterly basis, Liabilities from Discontinued Operations changed N/A year-over-year to $32.8 million in Q2 2024; TTM through Jun 2024 was $32.8 million, a N/A change from a year earlier, with the FY2023 full-year figure at $275.1 million, changed N/A from the prior year.
- Liabilities from Discontinued Operations was $32.8 million for Q2 2024 at Viatris, down from $234.8 million in the prior quarter.
- The five-year high for Liabilities from Discontinued Operations was $335.3 million in Q3 2022, with the low at $14.3 million in Q3 2023.
- Average Liabilities from Discontinued Operations over 3 years is $207.9 million, with a median of $275.1 million recorded in 2023.
- The largest YoY upside for Liabilities from Discontinued Operations was 95.74% in 2023 against a maximum downside of 95.74% in 2023.
- Over 3 years, Liabilities from Discontinued Operations stood at $335.3 million in 2022, then retreated by 17.95% to $275.1 million in 2023, then plunged by 88.08% to $32.8 million in 2024.
- The last three Liabilities from Discontinued Operations figures came in at $32.8 million (Q2 2024), $234.8 million (Q1 2024), and $275.1 million (Q4 2023), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.53 Bn | 38.88 Bn | 2.15 Bn |
| 2 | Viatris | 19.14 Bn | 18.25 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.45 Bn | 5.33 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.33 Bn | 492.63 Mn | 2.10 Bn |
| 6 | Alvotech | 1.51 Bn | 1.36 Bn | 2.56 Mn |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 400.20 Mn | 358.95 Mn | 17.15 Mn |
| 10 | RedHill Biopharma | 178.79 Mn | 178.79 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 32.80 Mn |
| Mar 31, 2024 | 234.80 Mn |
| Dec 31, 2023 | 275.10 Mn |
| Sep 30, 2023 | 14.30 Mn |
| Sep 30, 2022 | 335.30 Mn |
| Jun 30, 2022 | 285.10 Mn |
| Mar 31, 2022 | 277.70 Mn |